2014: Dulaglutide (Trulicity) is approved by the FDA, and is recognized as the first type 2 diabetes drug to reduce the risk of major adverse cardiovascular events (MACE)
The FDAs approval of resmetirom changes the MASH drug development landscape for the better after years of failed programs 3
The ADA also considers learning about diabetes and getting lifestyle and nutrition support core parts of a diabetes care plan [archived link]
MGH subsequently appointed Habener chief of its newly established Laboratory of Molecular Biology
conducted a pre-specified cardiovascular meta-analysis that included all seven randomized controlled trials with a duration of at least 26 weeks from the SURPASS trials [61]
GLP-1 and GIP control blood glucose levels by stimulating insulin secretion by pancreatic -cells while inhibiting glucagon secretion, increasing pancreatic -cell proliferation, and decreasing their apoptosis [3,4,5,6,7,8]